About - BMY :

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Employees - 34100, CEO - Dr. Christopher S. Boerner Ph.D., Sector - Healthcare, Country - US, Market Cap - 97.42B

Altman ZScore(max is 10): 1.95, Piotroski Score(max is 10): 7, Working Capital: $6713000000, Total Assets: $92427000000, Retained Earnings: $16106000000, EBIT: 8123000000, Total Liabilities: $74979000000, Revenue: $47636000000

- Current Price $47.87 - Analyst Target Price $56.05

Stats & Key Metrics
TickerBMY
IndexS&P 500
Curent Price 47.87
Change1.38%
Market Cap97.42B
Average Volume14.85M
Income5.42B
Sales47.64B
Book Value/Share8.54
Cash/Share5.79
Dividend Est2.49 (5.20%)
Dividend TTM2.44 (5.10%)
Dividend Ex-DateApr 04, 2025
Employees34100
Moving Avg 20days-0.09%
Moving Avg 50days-9.81%
Moving Avg 200days-11.63%
Shares Outstanding2.04B
Earnings DateApr 24 BMO
Inst. Ownership81.56%
Key Ratios & Margins
Price/Earnings17.97
Forwad P/E7.89
PE Growth0.25
Price/Sales2.05
Price/Book5.60
Price/Cash8.27
Price/FCF7.44
Quick Ratio1.17
Current Ratio1.28
Debt/Equity2.95
Return on Assets5.66%
Return on Equity31.99%
Return on Investment8.35%
Gross Margin59.16%
Ops Margin22.93%
Profit Margin11.38%
RSI45.39
BETA(β)0.37
From 52week Low21.65%
From 52week High-24.41%
Earnings & Valuation
EPS2.66
EPS next Year6.07
EPS next Qtr1.68
EPS this Year496.84%
EPS next 5 Year72.93%
EPS past 5 Year-
Sales past 5 Year15.21%
EPS Y/Y186.41%
Sales Y/Y4.62%
EPS Q/Q120.45%
Sales Q/Q-5.60%
Sales Surprise4.73%
EPS Surprise20.43%
ATR(14)1.61
Perf Week2.75%
Perf Month-2.19%
Perf Quarter-12.93%
Perf Year8.52%
Perf YTD-15.36%
Target Price56.05

AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer